Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Niu Y, et al. Oncogene. 2010 Jun 24;29(25):3593-604. doi: 10.1038/onc.2010.121. Epub 2010 May 3. Oncogene. 2010. PMID: 20440270 Review.
Androgen-deprivation therapy (ADT) for the suppression of androgens binding to the androgen receptor (AR) has been the norm of prostate cancer treatment. ...These contrasting clinical data suggest that differential androg
Androgen-deprivation therapy (ADT) for the suppression of androgens binding to the androgen receptor (AR)
New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.
Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L, Jiang Q, Huang CK, Niu Y, Yeh S, Chang C. Lee SO, et al. J Mol Cell Biol. 2013 Feb;5(1):14-26. doi: 10.1093/jmcb/mjs042. Epub 2012 Jul 24. J Mol Cell Biol. 2013. PMID: 22831834 Free PMC article.
The androgen deprivation therapy (ADT) to systematically suppress/reduce androgens binding to the androgen receptor (AR) has been the standard therapy for prostate cancer (PCa); yet, most of ADT eventually fails leadi …
The androgen deprivation therapy (ADT) to systematically suppress/reduce androgens binding to the androgen re